Navigation Links
Recent Research Reports and Near-Term Corporate Events
Date:2/6/2008

LARGO, Fla., Feb. 6 /PRNewswire-FirstCall/ -- GeoPharma, Inc. (Nasdaq: GORX) (the "Company") announced today in an effort to communicate its story to as wide of an audience as possible it has placed both of the recent research reports issued about the company on its website at http://www.GeoPharmainc.com under the "Analyst Coverage" tab in the "For Investors" section and that it will be speaking publicly several times in the next few months.

In the most recent research report issued by Andre Garnet of Red Chip, a one year price target of $8 per share was established.

Additionally, GeoPharma has a speaking engagement at the Red Chip Small Cap Investor Conference in Scottsdale, AZ on Thursday, February 7th at 10:10 AM MST.

For those unable to attend in person, the presentation may be viewed online by logging in to the following site: http://www.visualwebcaster.com/event.asp?id=45650.

Speaking about GeoPharma, Red Chip President David Gentry remarked, "GeoPharma is one of the most compelling small cap stories I have seen and is exactly the type of fast growing undervalued situation the retail and institutional clientele that attend our conferences find attractive."

GeoPharma will also be an attending presenter at the Spring EdgeWater Research Partners conference being held at the Grand Hyatt in Denver, Colorado on April 8, 2008. EdgeWater, an Independent research organization and subscription based newsletter just recently issued a research report of its own on GeoPharma, formulating a price target of $7.25 with an 18-24 month time horizon.

Commenting on GeoPharma, EdgeWater Research analyst and publisher Dave Lavigne stated, "GeoPharma's story is just starting to unfold; we are pleased to have them join us at the spring conference in April to communicate their most recent developments."

Furthermore, GeoPharma has announced that it plans to release its 3rd quarter earnings report prior to trading on Thursday, February 14, 2008. A conference call hosted by GeoPharma CEO Mihir Taneja and GeoPharma CFO Carol Dore-Falcone at 11:30 EST will be held the same day. Anyone wishing to listen to the live call may do so by dialing 1-888-680-0869 using pass code 78555682 at 11:25 am EST.

A replay of the call will also be available from 1:30 PM February 14th through the 21st by dialing 1-888-286-8010 pass code 37538422. A webcast of the conference call will also be available on the GeoPharma website.

About GeoPharma, Inc:

GeoPharma, Inc. is a rapidly growing Bio/Pharma company with a diversified business model participating in 3 main market segments: Specialty Pharma, Manufacturing, and Distribution. The Specialty Pharma division specializes in the formulation of generic drugs for human and veterinary usage and the development of medical devices used by oncologists and other medical professionals. The Manufacturing and Distribution divisions, manufacture, package, and distribute generic drugs, nutraceuticals, cosmetics, and functional food products for companies worldwide.

GeoPharma's growth strategy is to capitalize on its research and manufacturing expertise to develop medical devices and high margin generic drug products for niche markets with high barriers to entry. GeoPharma's competitive advantage in these areas is in its ability to navigate the challenges that such market pursuits present effectively.

Currently GeoPharma employs nearly 300 people and operates facilities in Florida, Maryland, Pennsylvania, Nevada, Rhode Island, and Texas utilizing over 330,000 Sq. Ft. of office, warehouse, manufacturing and laboratory facilities.

For further information visit the "For Investors" section of the GeoPharma website at http://www.geopharmainc.com.

This press release may contain statements, which constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries' expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without management's control. Important factors that could cause such differences are described in the company's periodic filings with the Securities and Exchange Commission.


'/>"/>
SOURCE GeoPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Bio-Identical Hormone Menopause Doctor Responds to Recent FDA News About Estriol
2. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
3. DelSite Nasal Powder Technology Could Reduce Recently Reported Waste in Federal Vaccine Program
4. ReBuilder Medical Technologies, Inc.s Recent Stock Price Volatility Explained
5. Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) Label Reflects Recommendations from Recent FDA Advisory Committee Meetings
6. National Stem Cell Holding in Final Stage Negotiations for Exclusive Licensing of its Recently Discovered Biomaterial for Anti-Aging Applications
7. Recent Study Confirms Alimentary Healths Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome
8. ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
9. Access Highlighted in Recent BusinessWeek Article
10. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
11. Xenon Announces Appointment of VP, Discovery Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 7, 2016 Regen BioPharma Inc. (OTCQB: ... of Molecular Sciences a team of scientists in ... have demonstrated that expression of NR2F6 in patients with early ... NR2F6 in patient,s cervical cancer tissue as well as in ... "This is an interesting study and the first that I ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... early access program for SmartBiome -- a novel metagenomic deep-sequencing research platform. ... enrichment and detection of hundreds of different genes. The selective early access ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... Group, the world’s largest privately-held contract pharmaceutical development and manufacturing organisation, ... leading biopharma outsourcing company combining a leading CRO and the industry’s only ...
(Date:12/6/2016)... , ... December 06, 2016 , ... ... plasma technology platforms, announced today that the company has engaged in a collaborative ... Development Agreement (MRDA) with the CSU Office of the Vice President for Research. ...
Breaking Biology Technology:
(Date:12/6/2016)... , Dec. 6, 2016 Valencell , the ... it has seen a third consecutive year of triple ... technology in 2016 with a 360 percent increase in ... This increase was driven by sales of its wrist ... interest in its technology for hearables for fitness and ...
(Date:12/5/2016)... , Dec. 5, 2016  The Office of ... published "Can CT Scans Enhance or Replace Medico ... potential of supporting or replacing forensic autopsies with ... scan. In response to recommendations made ... exploring using CT scans as a potential component ...
(Date:12/2/2016)... Texas , Dec. 1, 2016   ... today announced BioLock , an electrocardiogram (ECG) ... health monitoring, a key IoT asset. The smart ... into a vehicle,s steering wheel and mobile devices ... simple touch. As vehicle technology advances, ...
Breaking Biology News(10 mins):